Yahoo · Sep 8, 2026
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
NY
NASDAQ · NYXH
Nyxoah S.A.
Healthcare · Medical - Instruments & Supplies
$1.54
Up+$0.04 (+2.67%)
Updated Sep 12, 2026, 5:37 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 181.49M
- P/E ratio
- -1.85
- Dividend yield
- 0.00%
- 52-week range
- $1.26 – $3.66
- Volume
- 179.48K
- Avg. volume
- 58.93K
Price performance
NYXH price history
1M range · 20 trading sessions · Daily adjusted prices
NYXH closed at $1.54 after 20 trading sessions, down 4.94% for the selected period.
- Last close
- $1.54
- Period change
- -4.94%
- Period low
- $1.49
- Period high
- $1.76
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.54 | $1.57 | $1.51 | $1.54 | 179.48K |
| Sep 10, 2026 | $1.51 | $1.525 | $1.47 | $1.50 | 188.24K |
| Sep 9, 2026 | $1.56 | $1.56 | $1.505 | $1.52 | 237.86K |
| Sep 8, 2026 | $1.63 | $1.635 | $1.54 | $1.56 | 376.57K |
| Sep 4, 2026 | $1.74 | $1.81 | $1.59 | $1.62 | 1.01M |
| Sep 3, 2026 | $1.82 | $1.83 | $1.6501 | $1.76 | 4.59M |
| Sep 2, 2026 | $1.52 | $1.535 | $1.495 | $1.51 | 3.03M |
| Sep 1, 2026 | $1.54 | $1.5416 | $1.49 | $1.49 | 79.72K |
| Aug 31, 2026 | $1.62 | $1.62 | $1.55 | $1.56 | 105.89K |
| Aug 28, 2026 | $1.59 | $1.63 | $1.57 | $1.60 | 86.03K |
| Aug 27, 2026 | $1.64 | $1.64 | $1.57 | $1.57 | 100.93K |
| Aug 26, 2026 | $1.68 | $1.68 | $1.60 | $1.62 | 126.46K |
| Aug 25, 2026 | $1.63 | $1.66 | $1.605 | $1.64 | 156.74K |
| Aug 24, 2026 | $1.67 | $1.67 | $1.59 | $1.62 | 108.65K |
| Aug 21, 2026 | $1.64 | $1.65 | $1.585 | $1.60 | 164.07K |
| Aug 20, 2026 | $1.64 | $1.695 | $1.64 | $1.64 | 39.2K |
| Aug 19, 2026 | $1.63 | $1.67 | $1.59 | $1.65 | 156.39K |
| Aug 18, 2026 | $1.642 | $1.665 | $1.58 | $1.60 | 123.32K |
| Aug 17, 2026 | $1.59 | $1.63 | $1.59 | $1.60 | 55.68K |
| Aug 14, 2026 | $1.65 | $1.65 | $1.57 | $1.62 | 117.53K |
Latest NYXH news
The latest Smart Investors Daily articles mentioning NYXH.
Stock researchCompany · Overview
NYXH research
Overview
Company profile and research snapshot.
Company profile
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2026 | DEGROOF PETERCAM | Buy | — |
| Jul 7, 2026 | STIFEL EUROPE | Hold | — |
| Jul 7, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
| May 26, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
| May 21, 2026 | CANTOR FITZGERALD | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 8, 2026
Reported Earlier, Nyxoah Begins US Study Of Sleep Apnea Implant In First Patient
Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through
Yahoo · Sep 7, 2026
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to evaluate the long-term safety and effectiveness of the Genio therapy in real-world clinical practice First implant performed by Rolando Molina, MD, South Florida ENT Associates, with Edward Mezerhane, MD, of PharmaDev Clinical Research Institute as Site Principal Investigator Mont-Sain
Yahoo · Sep 2, 2026
Nyxoah Shares Jump After Genio Meets Primary Endpoints in CCC Patient Study
Nyxoah SA (NYXH) shares jumped 15% in Wednesday trading after it said its ACCCESS US pivotal study m
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
